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Signal transductionIn experimental membranous nephropathy, complement C5b-9 induces sublethal glomerular epithelial cell
(GEC) injury and proteinuria. C5b-9 also activates mechanisms that restrict injury or facilitate recovery. The
ubiquitin–proteasome system (UPS) selectively degrades damaged or abnormal proteins, while misfolded
proteins in the endoplasmic reticulum (ER) undergo ER-associated degradation (ERAD). In this study, we inves-
tigated the effect of complement on the UPS and ERAD. We monitored UPS function by transfection of rat GECs
with a UPS reporter, GFPu (CL1 degron fused with green ﬂuorescent protein). By analogy, CD3δ-yellow ﬂuores-
cent protein (YFP) was employed as a reporter of ERAD. We demonstrated decreased GFPu levels in GECs after
incubation with antibody and complement, compared with control. Using C8-deﬁcient serum with or without
puriﬁed C8, cycloheximide (an inhibitor of protein synthesis), and the proteasome inhibitor, MG132, we con-
ﬁrmed that the decrease of GFPuwasmediated by C5b-9, and subsequent proteasomal degradation of the report-
er. Inhibition of the c-Jun N-terminal kinase attenuated the effect of complement on GFPu degradation.
Complement, however, increased the level of CD3δ-YFP in GECs, implying an impairment of ERAD, likely due
to an overabundance of misfolded proteins in the ER. The overall ubiquitination of proteins was enhanced in
complement-treated GECs and in glomeruli of rats with experimental membranous nephropathy, although
ubiquitin mRNA was unchanged in GECs. Proteasome inhibition with MG132 increased the cytotoxic effect of
complement in GECs. Complement-stimulated UPS function, by accelerating removal of damaged proteins,
may be a novel mechanism to limit complement-induced injury.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The health of an organism largely depends on the exactness of
signals sent among constituent cells. Much of this information is trans-
mitted through proteins, which are either secreted from the cell, are
embedded in the plasma membrane, or are part of the intracellular
molecular network. Considering the high rate of translation, and that
stress may result in the incorporation of incorrect amino acids or the
disruption of proper protein folding, it becomes evident that protein
biogenesis is an inherently error-prone process. The endoplasmic retic-
ulum (ER) is an essential cellular compartment for protein maturation,oplasmic reticulum-associated
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rights reserved.and about one-third of all cellular proteins are translocated into the
lumen of the ER, where they are modiﬁed to form their proper tertiary
structure [1]. The quality of the protein folding process in the ER is vig-
orously controlled by molecular chaperones (e.g., BiP/GRP78, GRP94,
calnexin) [2,3]. Only correctly folded proteins are permitted to leave
the ER, while misfolded proteins are selected for degradation. One
important mechanism for a cell to clear misfolded proteins is through
targeted proteolysis by the ubiquitin–proteasome system (UPS).
UPS-mediated protein degradation involves tagging of the ε-NH2
group of an internal substrate lysine residue by covalent attachment
of multiple ubiquitin molecules and degradation of the tagged protein
by the 26S proteasome complex, with release of free and reusable
ubiquitin. Ubiquitin is attached to its substrate in a three step process
through an enzymatic cascade, comprising ubiquitin activase (E1),
one of several ubiquitin conjugases (E2s), and one of many different
ubiquitin ligases (E3s) [4]. Since the 76 amino acid ubiquitin molecule
contains seven lysine residues, which can each be targeted for ubiquitin
conjugation (i.e. ubiquitylation), consecutive rounds of ubiquitylation
can result in the formation of long and diverse ubiquitin chains [4].
The current paradigm states that attachment of at least four ubiquitin
moieties to the substrate is necessary for targeting to the 26S protea-
some [5,6]. In a last crucial step, the ubiquitin chain is removed from
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permit more efﬁcient translocation into the catalytic core for degrada-
tion [7]. UPS activity plays a role in regulating the level of proteins syn-
thesized in the ER. The process, which removes terminally misfolded
proteins from the ER, is known as ER-associated degradation (ERAD)
and requires retrograde transport of substrates to the cytoplasm, the
site of the 26S proteasome [8,9]. However, a broad spectrum of insults
can disrupt this process, causing accumulation of misfolded proteins
and failure of the ER to deal with this excessive protein load. Thus, the
term ER stress is used to deﬁne any perturbation that compromises
the protein folding functionality of the ER [10]. It is implicated in several
diseases, ranging from ischemia–reperfusion injury to neurodegenera-
tion (e.g. Alzheimer disease, Parkinson disease) to diabetes [11–13]. In
the kidney, there is also evidence for an important role for ER stress in
glomerular visceral epithelial cell (GEC; podocyte) injury [14–17].
Membranous nephropathy is an organ-speciﬁc complement-
mediated disease and a frequent cause of idiopathic nephrotic syn-
drome in adults. Morphologically, it is characterized by subepithelial
immune deposits containing IgG and complement, expansion of the
glomerular basement membrane, and diffuse effacement of podocyte
foot processes. In experimental membranous nephropathy, heterolo-
gous antibody binds to podocyte antigens [18,19]. Subsequently, im-
mune complex formation leads to activation of the complement
system with assembly of the C5b-9 membrane attack complex [19].
Generally, nucleated cells require multiple C5b-9 lesions for lysis, but
at lower doses, C5b-9 induces sublethal (sublytic) injury and various
metabolic effects [18,19]. InGECs, C5b-9 can activate cytosolic phospho-
lipase A2, protein kinase C, mitogen-activated protein kinase (MAPK)
pathways, cell cycle proteins, transcription factors, and others [18,19].
Recent studies have demonstrated that C5b-9-induced GEC injury is
associated with damage to the ER and an increased expression of ER
stress proteins in GECs in culture and in the passive Heymann nephritis
(PHN) model of membranous nephropathy in the rat [14,15].
In the present study, we investigated the effects of complement on
UPS and ERAD function in GECs. We employed proteasome and ERAD
reporters, and we analyzed changes in ubiquitination of proteins to
provide a global assessment of UPS activity, which includes the interac-
tions of E1, E2s, E3s, ubiquitin isopeptidases, togetherwith the degrada-
tive capability of the proteasome. Complement increased UPS activity
and protein ubiquitination, and proteasome inhibition exacerbated
complement cytotoxicity.2. Materials and methods
2.1. Materials
Tissue culture reagents and Lipofectamine 2000 were obtained
from Invitrogen (Burlington, ON). Cycloheximide, doxorubicin, E64,
N-ethylmaleimide, ionomycin, MG132, PD98059, SB203580, SP600125,
tunicamycin, C8-deﬁcient serum, C8, rabbit anti-ubiquitin antiserum,
mouse anti-tubulin antibody, and rabbit anti-actin antibody were
obtained from Sigma-Aldrich Canada (Mississauga, ON). N-Succinyl-
Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin (Suc-LLVY-AMC) was
from Biomol (Plymouth Meeting, PA). Electrophoresis and immuno-
blotting reagents were from Bio-Rad Laboratories (Mississauga, ON),
GE Healthcare (Baie d'Urfé, QC), and Jackson ImmunoResearch (West
Grove, PA). Rabbit anti-cyclin A, mouse anti-green ﬂuorescent protein
(GFP), mouse anti-hemagglutinin epitope (HA), and mouse anti-
ubiquitin antibodies, as well as U0126 were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). pEGFPu was kindly provided by Dr. Ron
Kopito (Stanford University, Stanford, CA) [20] and pHA-ubiquitin has
previously been described by Treier et al. [21]. CD3δ-yellow ﬂuorescent
protein (YFP)waspurchased fromAddgene andwasdescribedpreviously
[22]. The dominant negative c-Jun N-terminal kinase (JNK) cDNA
(JNKapf) was described previously [23].2.2. Cell culture and transfection
Primary cultures of GECs were established from explants of rat
glomeruli, and have been characterized previously [24,25]. GECs were
cultured in K1medium, and experiments were donewith cells between
passages 25 and 70. GECswere transiently transfected using a DNA (μg)
to Lipofectamine 2000 (μl) ratio of 1:2. Mouse embryonic ﬁbroblasts
were cultured in DMEMwith 10% fetal calf serum [15].2.3. Incubation of cells with antibody and complement
To activate complement, GECs in monolayer culture were incubat-
ed with rabbit anti-GEC antiserum (5% vol/vol) in modiﬁed Krebs–
Henseleit buffer containing 145 mM NaCl, 5 mM KCl, 0.5 mM MgSO4,
1 mM Na2HPO4, 0.5 mM CaCl2, 5 mM glucose, and 20 mM Hepes,
pH 7.4, for 40 min at 22 °C. GECs were then incubated with normal
human serum (NS; diluted in K1 medium), or with heat-inactivated
(decomplemented) human serum (HIS; 56 °C for 1 h) in controls, at
37 °C. In some experiments, antibody-sensitized GECs were incubated
with C8-deﬁcient human serum, or C8-deﬁcient serum reconstituted
with puriﬁed C8 (80 μg/ml undiluted serum). We have generally
used heterologous complement in order to facilitate studies with
complement-deﬁcient sera, and to minimize possible signaling
via complement-regulatory proteins, however, in earlier studies, we
conﬁrmed that homologous (rat) complement activated analogous sig-
naling pathways in GECs. Although there was some variability in con-
centrations of complement activity among batches of sera, we selected
2.5% as a “sublytic” concentration, i.e. a concentration that inducedmin-
imal cytolysis. In GECs, complement is not activated in the absence of
antibody [25]. To activate complement in mouse embryonic ﬁbroblasts,
the cells were incubated with antiserum, as described above, followed
by 5% NS (sublytic concentration), or HIS in controls [15].2.4. Immunoprecipitation and immunoblotting
To prevent deubiquitination of proteins, cell lysates were prepared
in buffer containing 1% Triton X-100, 125 mM NaCl, 10 mM Tris, 1 mM
EDTA, 1 mM EGTA, 20 μM pepstatin, 0.2 mM PMSF, and 10 mM
N-ethylmaleimide, pH 7.4. Lysates were incubated with primary anti-
body (non-immune IgG in controls), followed by agarose-coupled pro-
tein A. Immune complexes or cell lysates were boiled in Laemmli
sample buffer, and were subjected to SDS-PAGE under reducing condi-
tions. Equal amounts of proteins were loaded into each lane of the gel.
Proteins were then electrophoretically transferred onto nitrocellulose
paper, blocked with 5% bovine serum albumin, and incubated with
primary antibody, and then with horseradish peroxidase-conjugated
secondary antibody. The blots were developed using the enhanced
chemiluminescence technique (ECL). Protein content was quantiﬁed
by scanning densitometry, using NIH ImageJ software [14,15].2.5. RNA extraction and analysis
RNA extraction and cDNA synthesis was done by use of the RNeasy
Mini Kit and the QuantiTect Reverse Transcription Kit from Qiagen.
Reverse transcriptase real-time quantitative polymerase chain reaction
ampliﬁcation (RT-qPCR) was performed with a pair of target-speciﬁc
primers, and detection was with iTaq SYBR Green Supermix with ROX
from Bio-Rad Laboratories (Applied Biosystems 7300 Real-Time PCR
System). The primers for GFPu were 5′-GTCCAGGAGCGCACCATCT-3′
(forward) and 5′-ATGCCCTTCAGCTCGATGC-3′ (reverse). Standardization
of gene expression measurements was done against hypoxanthine ribo-
syltransferase (HPRT); primers 5′-TCGAAGTGTTGGATACAGGCCAGA-3′
(forward) and 5′-TACTGGCCACATCAACAGGACTCT-3′ (reverse).
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Cellswere scraped fromculture dishes into buffer containing 50 mM
Tris–HCl (pH 7.50), 250 mM sucrose, 5 mMMgCl2, 0.5 mMEDTA, 2 mM
ATP and 1 mM DTT (4 °C). After sonication, cells were centrifuged for
10 min at 10,000 g. Supernatants (30–50 μg protein in 50 μl) were
mixed with 50 μl of 50 mM Tris–HCl (pH 7.50), 40 mM KCl, 5 mM
MgCl2, 0.5 mM ATP, 1 mM DTT, 0.5 mg/ml BSA, and 0.2 mM Suc-LLVY-
AMC (chymotrypsin-like activity). Proteasomal activity was measured
after 30 min incubation at 37 °C, in a spectroﬂuorometer. The excitation
and emission wavelengths were 360 nm and 460 nm, respectively.
Preliminary studies demonstrated that in this assay, pretreatment of
cells with the proteasome inhibitor, MG132, inhibited chymotrypsin-
like activity by ~80%, indicating that the large majority of the activity
is associated with the proteasome.
2.7. Induction of passive Heymann nephritis
PHNwas induced inmale Sprague Dawley rats by a single injection of
0.4 ml of sheep anti-Fx1A antiserum, as described previously [14,26]. Rat
glomeruli were isolated utilizing a differential sieving technique. All
studies were approved by the McGill University Animal Care Committee.
2.8. Measurement of complement-dependent cytotoxicity
Complement-mediated cell lysis was determined by measuring
release of lactate dehydrogenase (LDH), as described previously [25].
Speciﬁc release of LDH was calculated as [NS−HIS]/[100−HIS],
where NS represents the percentage of total LDH released into cell su-
pernatants in incubations with NS, and HIS is the percentage of total
LDH released into cell supernatants in incubations with HIS [25].
2.9. Statistics
Data are presented as mean±SEM. Unless otherwise speciﬁed, a
two-tailed t-test was used to determine signiﬁcant differences between
two groups. One-way ANOVA was conducted to determine signiﬁcant
differences among groups. Two-way ANOVA was used when there
wasmore than one independent variable.Where signiﬁcant differences
were found, individual post-hoc comparisons were performed between
groups using the t statistic with adjustment of the α-level according to
the Bonferroni method.
3. Results
3.1. Complement increases UPS function as monitored by GFPu
Tomonitor the function of the UPS, GECs were transiently transfected
with the UPS reporter, GFPu, which consists of a 16 amino acid degron,
CL1, fused to the C-terminus of GFP. The CL1 degron was ﬁrst identiﬁed
in a yeast screen for sequences that destabilize β-galactosidase [27]. The
C-terminal bulky hydrophobic motif CL1 resembles a misfolded domain,
which in mammalian cells will target GFPu for ubiquitin-dependent deg-
radation by the proteasome if UPS function is normal [27]. Twenty four
hours after transfection, GECs were incubated with anti-GEC antibody
andNS at a sublytic concentration (to assemble C5b-9), or HIS in controls.
GFPu levels decreased in cells treated with NS in a time-dependent man-
ner, whereas in cells incubated with HIS, GFPu remained relatively stable
in these experiments (Fig. 1A and B). However, when GECs were trans-
fected with GFP (without the degron), treatment of GECs with 2.5% NS
did not reduce the level of GFP (Fig. 1C and D). To verify that complement
did not affect GFPu at a transcriptional level, GFPu mRNA in cell lysates
was analyzed using RT-qPCR. GFPu mRNA expression in GECs treated
with NS was not signiﬁcantly different from GFPu mRNA expression
in GECs treated with HIS (Fig. 1E). It should also be noted the
complement-induced reduction in the level of the GFPu reporter wasnot inﬂuenced by the level of reporter expression under control condi-
tions, implying that the change in GFPu was independent of GFPu trans-
fection efﬁciency (results not shown).
3.2. Decrease in GFPu expression is due to C5b-9 assembly and
proteasomal degradation
C8 is the key component of the C5b-9 membrane attack complex.
Incubation of GECs with C8-deﬁcient serum, which had been reconsti-
tuted with puriﬁed C8 (at a sublytic concentration), led to a signiﬁcant
decrease in the GFPu reporter, when compared with unreconstituted
C8-deﬁcient serum (Fig. 2A and B). Thus, the observed reduction in
GFPu expression was actually due to assembly of the C5b-9 membrane
attack complex. In some experiments, incubation with unreconstituted
C8-deﬁcient serum (i.e. assembly of C5b-7) appeared to reduce the
GFPu reporter, as compared with HIS; however, this reduction was not
consistent among experiments, and the mean levels of GFPu were not
signiﬁcantly different between HIS and unreconstituted C8-deﬁcient
serum groups (Fig. 2B). Nevertheless, based on the results in Fig. 2A
and B, an effect of C5b-7 or of early complement components on UPS
function cannot be excluded entirely.
Notably, the complement-induced reduction inGFPuwas blockedby
the proteasome inhibitor, MG132, conﬁrming that the reduction was
indeed due to proteasomal degradation (Fig. 2C and D). To verify that
decreased GFPu levels were not the result of reduced protein synthesis,
GECs were transiently transfected with GFPu, and after 24 h, the cells
were incubated with antibody and complement in the presence of
cycloheximide,with andwithoutMG132 for a further 4 h. Cycloheximide
inhibits protein synthesis by blocking translational elongation in
eukaryotic organisms. The presence of cycloheximide did not affect
the complement-induced reduction in GFPu (Fig. 2E and F), indicating
that the reduction in GFPu was due to increased degradation and not
reduced synthesis.
3.3. Effect of complement on cyclin A
Cyclins are a family of proteins which control the progression of
cells through the cell cycle by activating cyclin-dependent kinases.
Ubiquitin-mediated proteolysis is one of the key mechanisms under-
lying cell cycle control, as cyclins are degraded through the UPS [4].
To extend the GFPu reporter ﬁndings to an endogenous protein, we
incubated untransfected GECs with antibody and sublytic NS or HIS,
in the presence of cycloheximide for 4 h. Treatment with NS led to a
signiﬁcant decrease of cyclin A levels, which could be completely
reversed by adding MG132 (Fig. 3A and B). Therefore, by analogy to
the exogenous GFPu reporter, complement reduced the levels of an
endogenous protein via UPS-mediated degradation. The effect of
complement on the decrease in cyclin A was smaller, compared with
GFPu; however, reporters such as GFPu have the advantage of being
speciﬁcally designed and optimized to measure UPS function, and are
more likely to show greater changes, compared with endogenously
expressed proteins.
3.4. Protein ubiquitination, and proteasome enzymatic activity
The studies described above showed that incubation of GECs with
complement resulted in enhanced degradation of proteins by the
UPS. In the next series of experiments, we assessed the effect of com-
plement on ubiquitination of proteins. GECs were incubated with anti-
body and complement (HIS in controls), in the presence or absence of
MG132 (to prevent proteasomal degradation of ubiquitinated pro-
teins). Then, lysates were immunoblotted with anti-ubiquitin antibody.
Total protein ubiquitination was increased in GECs treated with com-
plement (NS), compared to GECs treated with HIS (Fig. 4A and B).
Levels of ubiquitination were similar at 6 and 24 h. Co-incubation
with MG132 increased protein ubiquitination, but nevertheless levels
Fig. 1. Incubation of GECs with complement decreases GFPu expression. A and B: GECs were transiently transfected with GFPu. After 24 h, GECs were incubated with anti-GEC antibody
(5% v/v) and normal serum (NS) at a sublytic concentration (2.5% v/v; to assemble C5b-9) or heat-inactivated serum (HIS) in controls, for 1, 2, 4, or 6 h at 37 °C. Lysates were immuno-
blottedwith anti-GFP antibody. GFPu protein (~30 kDa) decreased in cells treatedwith NS (half-life ~3 h), comparedwithGECs treatedwith HIS (stable for up to 6 h), P=0.019 NS vsHIS,
5 experiments. C and D: GECswere transfectedwith GFP (without the CL1 degron). Therewas no signiﬁcant effect of 2.5% NS on the level of GFP, 5 experiments. E: GECswere transfected
with GFPu and subsequently incubatedwith 2.5%NS orHIS for 4 h. RNAwas extracted and analyzed using RT-qPCR. GFPumRNAvalues (arbitrary units)were normalized for HPRTmRNA.
GFPu mRNA expression in GECs treated with NS was not signiﬁcantly different from HIS. C(0) denotes the level of mRNA prior to incubation with antibody and complement.
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(Fig. 4A and B). Importantly, ubiquitin mRNA levels were not signiﬁ-
cantly affected by treatment with complement (Fig. 4C).Fig. 2. Decrease in GFPu protein expression is due to C5b-9 assembly and proteasomal degrad
which was reconstituted with puriﬁed C8 (C8DS+C8), for 4 h led to a decrease in the GFPu
GFPu after incubation with C8DS was not signiﬁcantly different, compared with HIS. *Pb0.00
induced reduction in GFPu was blocked by addition of the proteasome inhibitor MG132 (M
*P=0.0066 NS vs NS+MG, P=0.0027 NS vs HIS, 3 experiments. E and F: The complement-
decreased GFPu is not a result of a complement-induced decrease in protein synthesis, transie
protein synthesis inhibitor, cycloheximide (25 μg/ml) for 4 h. GFPu levels decreased when GECWe also assessed the ubiquitination of the GFPu reporter. GECs were
co-transfectedwith GFPu and HA-ubiquitin cDNAs [21]. After 48 h, cells
were treated for 4 h with sublytic NS or HIS, in the presence of MG132ation. A and B: Incubation of antibody-sensitized GECs with C8-deﬁcient serum (C8DS),
reporter, compared with unreconstituted C8DS (which assembles C5b-7). The level of
01 NS vs HIS, **P=0.009 C8DS+C8 vs C8DS, 4 experiments. C and D: The complement-
G; 25 μM), conﬁrming that the decrease in GFPu was due to proteasomal degradation,
induced reduction in GFPu occurs in the presence of cycloheximide. To demonstrate that
ntly transfected GECs were treated with antibody and 2.5% NS or HIS in the presence of a
s were treated with NS, *P=0.0006 NS vs HIS, 3 experiments.
Fig. 3. Effect of complement on cyclin A in GECs. A and B: GECswere treatedwith 2.5% NS
or HIS, in the presence of cycloheximide (25 μg/ml), for 4 h. Cell lysates were immuno-
blotted with antibody to cyclin A (CyA). Treatment with NS led to a signiﬁcant decrease
of cyclin A levels, compared with HIS, and the effect of NS was completely reversed by
MG132 (MG; 25 μM). *P=0.0417 NS vs HIS, P=0.0021 NS vs NS+MG, one-tailed
t-test, 3 experiments.
Fig. 4. Effect of complement on theUPS. A andB:UntransfectedGECswere incubatedwith antib
lysates were immunoblotted with anti-ubiquitin antibody. Total protein ubiquitination was s
withoutMG132 at both 6 and 24 h. *P=0.0032 NS vs HIS, **P=0.0267 NS+MG vs HIS+MG a
protein prior to incubation with antibody and complement. C: GECs were incubated with 2.5%
(arbitrary units) were normalized for HPRT mRNA. D: To assess ubiquitination of the GFPu rep
treated for 4 hwith 2.5%NS orHIS, in the presence ofMG132 (25 μM). Cell lysateswere immuno
complexeswere immunoblottedwith antibody to HA to assess the extent of GFPu ubiquitination
with anti-GEC antibody and 2.5% NS, or HIS in controls, for 1, 4, and 24 h at 37 °C. Proteasome ac
decreased the chymotrypsin-like activity of the 20S proteasome. P=0.014 NS vs HIS, 3 experi
1011T.M. Kitzler et al. / Biochimica et Biophysica Acta 1823 (2012) 1007–1016(to block proteasomal degradation of the ubiquitinated reporter), and
lysates were immunoprecipitated with anti-GFP antibody. GFPu was
ubiquitinated in complement-treated and in control cells. Although
we could not consistently detect a greater increase in ubiquitination
in complement-treated cells (Fig. 4D, upper panel), the amount of
GFPu protein was lower in complement-treated cells (Fig. 4D, lower
panel), implying that proteasomal degradation of GFPu was not blocked
completely, and that the reporter was, therefore, relatively more ubi-
quitinated in the complement-treated cells.
To assess the enzymatic activity of the proteasome, GECswere incu-
batedwith anti-GEC antibody and sublytic NS, or HIS in controls for 1, 4,
and 24 h. Proteasome chymotrypsin-like activitywasmonitored using a
ﬂuorogenic peptide substrate (Suc-LLVY-AMC). Incubation of GECs
with antibody and complement revealed a modest, but signiﬁcant
decrease (10–30%) in chymotrypsin-like activity of the 20S proteasome
(Fig. 4E). Therefore, enhanced degradation of GFPu was unlikely to
have been related to an increase in the enzymatic activity of the 20S
proteasome.
3.5. Total protein ubiquitination increases in experimental
membranous nephropathy
GEC injury and proteinuria in the PHN model of experimental
membranous nephropathy are mediated by C5b-9 [18,19]. In a next
set of experiments, we examined total protein ubiquitination in PHN.
Fourteen days after disease induction, glomerular extracts of rats
with PHN demonstrated signiﬁcantly higher levels of total proteinody and 2.5%NSorHIS for 6 or 24 h in the presence or absence ofMG132 (MG; 25 μM). Cell
igniﬁcantly increased in GECs treated with complement (NS), compared to HIS, with or
t 6 and 24 h, two-way ANOVA, 3 experiments. C(0) denotes the level of polyubiquitinated
NS or HIS for 4 h. RNA was extracted and analyzed using RT-qPCR. Ubiquitin mRNA values
orter, GECs were co-transfected with GFPu and HA-ubiquitin cDNAs. After 48 h, cells were
precipitatedwith anti-GFP antibody (+), or non-immune IgG (−; control). Subsequently,
, or anti-GFP. The immunoblot is representative of 3 experiments. E: GECswere incubated
tivity wasmeasured using a ﬂuorogenic peptide substrate (Suc-LLVY-AMC). Complement
ments.
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fore, the effect of complement on protein ubiquitination in cultured
GEC was paralleled in vivo. There was a trend towards increased levels
of total protein ubiquitination in PHN on day 5; however, the increase
did not reach statistical signiﬁcance (data not shown). Rats with PHN
demonstrated signiﬁcant proteinuria (Fig. 5C).
3.6. Functional role of ubiquitination
In these studies, we assessed the potential role of the proteasome in
mediating complement cytotoxicity. Antibody-sensitized GECs were
incubated with NS at two concentrations. This protocol allows for com-
plement to activate the cells, but with increasing complement dose, a
portion of the cells will undergo lysis, as quantiﬁed by release of LDH
[14,15,28]. Inhibition of the proteasome with MG132 enhanced com-
plement lysis, implying that activation of the UPS protects GECs from
complement cytotoxicity (Fig. 6). MG132 had no signiﬁcant cytotoxic
effect in control incubations (i.e. incubations with HIS). Since MG132
can potentially inhibit calpain (a calcium-dependent, non-lysosomal
cysteine protease),we alsomonitored complement lysis in thepresence
of E64, a compound that irreversibly inhibits calpains and other cysteine
proteases, but not the proteasome [29,30]. E64 had no signiﬁcant effect
on complement lysis, indicating that the effect ofMG132wasmost likely
speciﬁc to proteasome inhibition (Fig. 6).
3.7. Effect of complement on ERAD
GFPu is a reporter of ubiquitination and proteasomal degradation in
the cytosol (and nucleus). In the next set of experiments, we examined
the effect of complement on ERAD, which involves deglycosylation of
proteins in the ER, as well as interactions with lectins, prior to transit
from the ER to the cytosol for ubiquitination and proteasomal degrada-
tion.We transiently transfected GECs with CD3δ-YFP, an ERAD reporter
[22]. CD3δ-YFP is a fusion protein of the T-cell receptor subunit CD3δ
and YFP. In cells lacking the T-cell receptor, CD3δ-YFP is initially
retained in the ER, and its ubiquitination and degradation by the protea-
some is dependent on translocation from the ER to the cytoplasm [31].
After incubation of GECs with antibody and HIS, there was a decline in
the level of CD3δ-YFP at 6 h, with a further decline at 24 h (Fig. 7A
and B). This decline could be attenuated by treatment of GECs with
MG132 (data not shown). Incubation of GECs with complement (NS)
reduced the time-dependent decrease in the ERAD reporter signiﬁcantly,
both at 6 and 24 h (Fig. 7A and B). In addition, incubation of antibody-
sensitized GECs with C8-deﬁcient serum, which had been reconstituted
with puriﬁed C8, signiﬁcantly reduced the degradation of CD3δ-YFP,
when compared with unreconstituted C8-deﬁcient serum (Fig. 7C and
D), indicating that the effect of complement on the degradation of
CD3δ-YFP was indeed mediated via C5b-9.Fig. 5. Total protein ubiquitination in experimental membranous nephropathy. A and B: Fo
lysates were immunoblotted for ubiquitin. Rats with PHN (N=7) had signiﬁcantly highe
C: Urine protein excretion was signiﬁcantly higher in PHN. **P=0.0091 PHN vs Ctrl.Previous studies have demonstrated a role for ER stress in comple-
ment C5b-9-mediated GEC injury [14,15]. To determine if the effect of
complement on CD3δ-YFP may have been related to the induction of
ER stress, we examined the degradation of the ERAD reporter after
treatment of GECs with tunicamycin, a compound that inhibits of
N-glycosylation of proteins in the ER and thereby induces protein mis-
folding and ER stress [14]. Treatment of GECs expressing CD3δ-YFP
with tunicamycin led to an increase in the level of CD3δ-YFP, compared
with control (Fig. 7E and F), suggesting that accumulation of misfolded
proteins in the ER overwhelmed ERAD capacity, thereby reducing deg-
radation of CD3δ-YFP [22]. There was a ~10 kDa mobility shift of CD3δ-
YFP after treatment of cells with tunicamycin. This most likely reﬂects
tunicamycin inhibition of N-glycosylation, since CD3δ is known to
carry an N-glycosylation site and glycosylation of T-cell receptor sub-
units is a known mechanism to modulate avidity [32,33].
In view of the above results, we also examined the effect of ER stress
on the GFPu reporter. GECswere incubatedwith tunicamycin, aswell as
with the Ca2+ ionophore, ionomycin, a compound that can induce ER
stress in GECs, but also results in changes in intracellular Ca2+ concen-
tration [14]. In contrast to complement, incubation of GECswith tunica-
mycin had no signiﬁcant effect on GFPu (Fig. 8A and B). Incubationwith
ionomycin for 6 h signiﬁcantly increased GFPu, while incubation for
24 h had no signiﬁcant effect. These results do not replicate previous
reports demonstrating that ER-stress interfered with proteasomal
degradation of GFPu, although the previous reports showed only a
mild effect; moreover, our results suggest that the effect of complement
on GFPu degradation occurs independently of the complement effect on
the ER [20,22,34].
3.8. Speciﬁcity of the complement effect on UPS activity
To determine if the reduction of GFPu is uniquely induced by com-
plement, we examined the effect of doxorubicin (adriamycin) on
GFPu, since it was previously reported that doxorubicin can act on
both the ubiquitination apparatus and the proteasome. In a transgenic
mouse that expresses GFPdgn (a proteasome reporter similar to GFPu)
ubiquitously, intraperitoneal injection of doxorubicin signiﬁcantly re-
duced GFPdgn protein levels in the heart [35]. Moreover, doxorubicin
speciﬁcally targets GECs, and when administered in vivo, can induce
GEC injury and proteinuria [14]. To investigate whether doxorubicin
could decrease GFPu levels in the GEC culture model, GECs were tran-
siently transfected with GFPu and were treated with doxorubicin for
6 h. In agreement with the ﬁndings in transgenic mice, we could dem-
onstrate a signiﬁcant decrease in GFPu levels after treating GECs with
doxorubicin (Fig. 8C and D). Addition of MG132 inhibited the reduction
in GFPu in both doxorubicin-treated and untreated cells (Fig. 8C and D),
conﬁrming proteasomal degradation. These ﬁndings indicate that an
increase in UPS function in GECs is not limited to complement.urteen days after induction of PHN, glomeruli were isolated by differential sieving and
r levels of ubiquitin, compared with controls (Ctrl; N=6). *P=0.00098 PHN vs Ctrl.
Fig. 6. Role of proteasome function in complement-mediated cytotoxicity. GECs were
incubated with anti-GEC antibody and NS at 2.5% or 5% v/v, or HIS in controls, for 1 h.
Complement cytotoxicity was monitored as release of LDH. Inhibition of the proteasome
with MG132 (MG; 25 μM) increased complement-mediated cytotoxicity. Addition of
E64 (25 μM), which does not block the proteasome, but inhibits calpain, did not affect
the complement-mediated release of LDH. *P=0.0038 NS vs NS+MG, two-way
ANOVA, 5 experiments.
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GFPu is speciﬁc to GECs or ismore generalized, by performing analogous
experiments in mouse embryonic ﬁbroblasts. We employed a protocol
for antibody-mediated complement activation that we utilized earlier
in these cells [15]. In contrast to GECs, complement did not affect the
level of GFPu in the mouse embryonic ﬁbroblasts (Fig. 8E).Fig. 7. Effect of complement and ER-stress on ERAD. A and B: GECs were transiently transfect
in controls, for 6 or 24 h. C(0) denotes the level of CD3δ-YFP prior to incubation with antib
compared with HIS at both 6 and 24 h. *P=0.029 NS vs HIS at 6 and 24 h, two-way ANOVA, 3
(C8DS), which was reconstituted with puriﬁed C8 (C8DS+C8), for 6 h led to a smaller decr
HIS and C8DS+C8 vs C8DS, 3 experiments. E and F: GECs were incubated with tunicamycin
camycin (Tm, 10 μg/ml), compared with untreated control (Ctrl). *Pb0.00001 Tm vs Ctrl, 33.9. The effect of complement on GFPu is, in part, mediated via JNK
Previous studies demonstrated that assembly of C5b-9 leads to the
activation of the extracellular signal-regulated kinase (ERK), JNK, and
p38 MAPK [18,19]. In this series of experiments, we assessed the
potential role of protein kinases in regulating UPS activity, as measured
by GFPu. The complement-induced decrease in GFPu was attenuated sig-
niﬁcantly by the JNK inhibitor, SP600125 (Fig. 9A and D). In contrast, the
ERK pathway inhibitor, PD98059, did not attenuate the complement-
induced decrease in GFPu (Fig. 9B). The mean complement-induced
decreases in GFPu levels (compared with HIS control; quantiﬁed by
densitometry) were 40% in the presence of PD98059 vs 47% without
PD98059 (4 experiments). Similarly, another ERK pathway inhibitor,
U0126, did not affect the complement-induced decrease in GFPu (result
not shown). The p38 kinase pathway inhibitor, SB203580 was also inef-
fective in blocking UPS activation (Fig. 9B). The average complement-
induced decreases in GFPu (compared with HIS control) were 65% in
the presence of SB203580 vs 51% without SB203580 (2 experiments).
In earlier studies, we demonstrated that when used at comparable
concentrations, these inhibitors actually blocked complement-mediated
activation of ERK or p38 [19,23].
To conﬁrm a role for JNK in the regulation of UPS activity, we co-
transfected GECs with GFPu and a dominant negative mutant of JNK
(JNKapf). Complement-induced degradation of GFPu was attenuated
signiﬁcantly in GECs co-transfected with JNKapf, compared with
GECs that were co-transfected with control vector (Fig. 9C and E).ed with CD3δ-YFP and were then incubated with anti-GEC antibody and 2.5% NS, or HIS
ody and complement. The decrease in CD3δ-YFP was lower in cells incubated with NS,
experiments. C and D: Incubation of antibody-sensitized GECs with C8-deﬁcient serum
ease in the CD3δ-YFP reporter, compared with unreconstituted C8DS. *Pb0.0001 NS vs
(Tm, 10 μg/ml) for 24 h. The decrease in CD3δ-YFP was lower in the presence of tuni-
experiments.
Fig. 8. Speciﬁcity of the complement effect on UPS activity. A and B: GECs were incubated with ionomycin (Iono, 1 μM), or with tunicamycin (Tm, 10 μg/ml) for 6 or 24 h. Ionomycin
increased GFPu expression at 6 h. *P=0.016 Iono vs Control (Ctrl). Ionomycin (24 h) and tunicamycin (6 and 24 h) had no signiﬁcant effect on GFPu, 6 experiments. C and D: Incubation
of GECs with doxorubicin (Dox, 50 μg/ml) in the presence or absence of MG132 (MG; 25 μM) for 6 h led to a signiﬁcant decrease of GFPu expression, compared with untreated (UT).
*P=0.017 Dox vs UT, **Pb0.0001 Dox+MG vs UT+MG, 3 experiments. E: Complement (NS) does not decrease GFPu inmouse embryonic ﬁbroblasts. Cells were transiently transfected
with GFPu. After 24 h,ﬁbroblastswere incubatedwith anti-GEC antibody (5% v/v) andNS at a sublytic concentration (5.0% v/v) orHIS in controls, for 6 h at 37 °C.MG132 (MG; 25 μM)was
included in some incubations. Lysates were immunoblotted with anti-GFP antibody (immunoblot is representative of 2 experiments).
1014 T.M. Kitzler et al. / Biochimica et Biophysica Acta 1823 (2012) 1007–1016Thus, JNK, at least in part, mediates the effect of complement on the
UPS.
4. Discussion
The present study demonstrates that UPS function was enhanced in
GECs subjected to complement attack, as reﬂected by enhanced degra-
dation of GFPu and cyclin A (Figs. 1–3), exogenous and endogenous
reporters of the UPS, respectively. In parallel, ERAD function, monitored
by CD3δ-YFP, was impaired (Fig. 7), most likely in association with an
overabundance of misfolded proteins in the ER. It is reasonable to
conclude that the complement-induced increase in UPS function was,
at least in part, related to an increase in protein ubiquitination, rather
than an augmentation in proteasomal degradation. This view is sup-
ported by the ﬁnding that treatment of GECswith complement reduced
20S proteasome activity slightly, whereas total protein ubiquitination
was increased signiﬁcantly, even in the presence of a proteasome inhib-
itor (Fig. 4). The result of the 20S proteasome activity assaymay seem to
contradict the UPS reporter result. However, GFPu reporter assays have
the advantage of being functional assays that take into consideration
the function of the entire UPS [20,22]. The observed increase in UPS
function after exposure of cells to complement (decreased GFPu levels)
suggests that the effect of complement on overall UPS activity is outside
of the 20S proteasome, and may involve enhanced conjugation of
ubiquitin, although changes in deubiquitination cannot be excluded.
Moreover, a modest reduction in 20S proteasome activity is unlikely
to impair overall UPS function [20,36].
To investigate if the UPS is functionally relevant to complement-
mediated GEC injury, we studied the effect of proteasome inhibition
on complement lysis. In previous studies, increases in complement
lysis in the GEC culture assay were generally paralleled by increases in
proteinuria in vivo [14,18]. In the present study, we demonstratedthat the cytotoxic effect of complement was increased when protea-
some functionwas inhibited (Fig. 6). In vivo, GECs/podocytes are highly
differentiated cells that play an important role inmaintaining glomerular
permselectivity [18,19]. Signiﬁcant protein turnovermay be required for
podocytes to maintain their highly organized structure, and perturba-
tions of the protein handling capacity in the ERmay affect the functional
integrity of podocytes. In fact, ER stress is evident in podocyte injury
[14–17]. An important mechanism for cells to protect themselves from
the accumulation of misfolded proteins (i.e. proteotoxicity) is through
the degradation of proteins by the UPS. Our results are in support of
enhanced UPS function as a mechanism that protects podocytes from
complement attack. Indeed, it was recently reported that administration
of a proteasome inhibitor to rats with PHN exacerbated proteinuria, con-
sistent with the result of our complement cytotoxicity assay in cultured
GECs (Fig. 6) [37].
Increased activity of the UPS, asmonitored by the GFPu reporter,was
also induced by doxorubicin in GECs (Fig. 6). This result is in keeping
with a previous study, where it was shown in a transgenicmouse carry-
ing a proteasomal reporter that doxorubicin led to an increase in UPS
activity [35,38]. In experimental animals, doxorubicin can induce GEC
injury and proteinuria [14], which resembles human minimal change
disease or focal segmental glomerulosclerosis. One can speculate that
the enhancement of UPS function may also be a mechanism to limit
GEC injury in other glomerulopathies. Interestingly, doxorubicin has
been shown to increase UPS activity through upregulation of the
E3-ligase C-terminus of Hsc70-interacting protein (CHIP) via a post-
transcriptional mechanism, thereby leading to lower levels of proteo-
toxicity [38,39].
We and others have demonstrated that complement activates a
number of intracellular signaling pathways. The mediators include
several protein kinases, such as ERK, JNK, p38 [18,19]. By using inhibitors
or genetic approaches, we showed that the complement-mediated
Fig. 9. The effect of complement on GFPu is, in part, mediated via JNK. A, B, and D: GECs were transiently transfectedwith GFPu. After 24 h, cells were treatedwith anti-GEC antibody and
NS, or HIS in controls, for 4 h, in the presence or absence of the JNK inhibitor, SP600125 (10 μM),MAPK/ERK1 inhibitor, PD98059 (50 μM), or the p38 kinase inhibitor, SB203580 (10 μM).
SP600125 partially inhibited the NS-induced reduction in GFPu (A andD). D: *Pb0.0001NS vsHIS, **P=0.045NS vsNS+SP600125, 5 experiments. PD98059 and SB203580did not affect
the complement-induced reduction in GFPu (B). C and E: GECs were co-transfected with GFPu and a dominant negative mutant of JNK (JNKapf), or with GFPu and vector. After 24 h, cells
were incubatedwith anti-GEC antibody and NS (2.5% v/v), or HIS in controls, for 4 h. C(0) denotes the level of GFPu prior to incubationwith antibody and complement. In cells transfected
with empty vector, NS induced a reduction in GFPu. E: *P=0.018 NS vs HIS (vector), 3 experiments. After incubation with NS, the cells transfected with JNKapf had signiﬁcantly higher
levels of GFPu, compared with the cells transfected with the empty vector. **P=0.0017 NS+JNKapf vs NS+vector. Furthermore, in the JNKapf-transfected cells, NS treatment did not
reduce GFPu signiﬁcantly, compared with HIS, and in the cells incubated with HIS, GFPu was not signiﬁcantly different between JNKapf and vector transfections.
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pathways were not involved (Fig. 9). Recent studies support phosphory-
lation as amechanism for regulating E3 ubiquitin ligase activity [40]. One
candidate for future studies is Itch, an E3 ubiquitin ligase. Itch contains
MAPK phosphorylation sites and a D domain-like sequence, which is re-
quired for recognition by JNK isoforms. JNK can phosphorylate Itch,
thereby causing a conformational change, which leads to increased ubi-
quitination of the transcription factor, JunB [41]. Previously, we showed
that activation of JNK by complement was cytoprotective [28], although
the previous studies did not implicate speciﬁc mechanism(s) of cytopro-
tection. Based on the present study, it is reasonable to propose that the
cytoprotective action of JNK is, at least in part, mediated through the
UPS. The role of JNK in modulating the UPS and its mechanism of action
will require further study, in particular, examination of the functional
role of JNK in ubiquitination and GEC injury in vivo.
There are some limitations to the interpretation of the UPS reporter
results. Important modiﬁcations of proteins occur in the ER, where
chaperones assist the folding of glycoproteins until they achieve their
proper tertiary structure [2]. Proteins, which do not fold correctly after
several attempts, undergo ERAD, i.e. misfolded proteins are retrotran-
slocated from the ER into the cytoplasm, where they are degraded by
the proteasome [8,9]. GFPu is localized in the cytoplasm (as well as
nucleus) [20], and since its proteasomal degradation does not involve
translocation from the ER, it may not be a reporter sufﬁciently sensitive
to assess the effect of complement signaling on ERAD. This view is cor-
roborated by the ﬁnding that the level of GFPu expression in GECs was
not affected signiﬁcantly by ER-stress inducers (Fig. 8). Using CD3δ-YFP, we showed that the level of this ERAD reporter [22,31] was in-
creased after treatment of GECs with complement (Fig. 7). This result
suggests that while overall activity of the UPS was upregulated in
complement-induced GEC injury, misfolded proteins did accumulate
in the ER, likely due to an increased amount of misfolded proteins com-
peting for ER-resident enzymes, ER chaperones, and/or disrupted pro-
tein retrotranslocation to the proteasome. Degradation of CD3δ-YFP
was nonetheless dependent on proteasome function. Furthermore,
treatment of GECwith tunicamycin increased CD3δ-YFP levels, conﬁrm-
ing that accumulation of misfolded proteins in the ER can impair ERAD
in GECs. In summary, while overall UPS-function was increased, ERAD
was disrupted in complement-induced GEC injury.
Onemust be cautiouswhen extrapolating from results in cell culture
models to in vivo disease mechanisms. Unfortunately, it is not practical
to employ UPS reporters in rats in vivo, and while transgenic UPS re-
porter mice exist, mice are not susceptible to the induction of PHN
[18]. However, the complement-induced increase in protein ubiquitina-
tion observed in GEC culture (Fig. 4) was also evident in PHN (Fig. 5).
These results are in keeping with recent studies, which also showed
increased polyubiquitination of glomerular proteins in PHN, as well as
increased glomerular ubiquitin in human membranous nephropathy
[37,42]. Furthermore, ubiquitin C-terminal hydrolase-L1, an enzyme
with both ubiquitin ligase and deubiquitinating activities, has been
implicated in altering glomerular ubiquitination and development of
proteinuria in PHN [37]. Another recent study, which employed micro-
array to examine gene expression in PHN, showed that development of
nephritis was associated with increased expression of various genes
1016 T.M. Kitzler et al. / Biochimica et Biophysica Acta 1823 (2012) 1007–1016encoding ubiquitin-conjugating enzymes, as well as deubiquitinating
enzymes [43]. Studies aimed at further elucidating the precise mecha-
nisms regulating UPS function in complement-mediated cellular injury
will be required to fully understand the role of the UPS in disease path-
ogenesis, and to open new possibilities for future therapeutic strategies.
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